EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia

Tony Marchand iD, Cédric Pastoret iD, Gandhi Damaj, Angélique Lebouvier, Charles Herbaux iD, Aline Moignet, Miguel Pavlosky, Astrid Pavlosky iD, Anaise Blouet, Martin Eloit, Vincent Launay, Pierre Lebreton and 5 more

British Journal of Haematology · 2024-09 · 205 (3) · 915-923

DOI: 10.1111/bjh.19476 ↗

At a glance

Journal article in British Journal of Haematology, published online on 2024-04-19. Written by Tony Marchand and 16 co-authors. Institution: Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France. Major MEDLINE topics: Nitriles, Pyrazoles, Pyrimidines, Leukemia, Large Granular Lymphocytic. Cited 14 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells. Despite a usually indolent evolution, most patients will require a treatment over the course of the disease because of cytopenia or symptomatic associated autoimmune disorders. First‐line treatment is based on immunosuppressive agents, namely cyclophosphamide, methotrexate and ciclosporin. However, relapses are frequent, and there is no consensus on the management of relapsed/refractory patients. The implication of the JAK/STAT pathway in the pathogenesis of this disease has prompted our group to propose treatment with ruxolitinib. A series of 21 patients who received this regimen is reported here. Ten patients (47.6%) were refractory to the three main immunosuppressive drugs at the time of ruxolitinib initiation. Ruxolitinib yielded an overall response rate of 86% ( n = 18/21), including 3 complete responses and 15 partial responses. With a median follow‐up of 9 months, the median response duration was 4 months. One‐year event‐free survival and 1‐year overall survival were 57% and 83% respectively. Mild side effects were observed. Biological parameters, notably neutropenia and anaemia, improved significantly, and complete molecular responses were evidenced. This study supports ruxolitinib as a valid option for the treatment of relapsed/refractory LGL leukaemia.

Subjects

MeSH terms (MEDLINE)

NitrilesPyrazolesPyrimidinesLeukemia, Large Granular LymphocyticHumansFemaleMaleMiddle AgedAgedAged, 80 and overAdultRecurrenceTreatment Outcome

Author keywords

T‐cell lymphomachronic T cell leukaemiaclinical studieslymphoproliferative diseasemolecular biology

Substances

NitrilesPyrazolesruxolitinibPyrimidines

Authors and institutions

  • Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Université de Rennes, Rennes, France.
  • UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.
  • Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Institut d'Hématologie, Centre Hospitalier Universitaire de Caen, Caen, France.
  • Service d'Hématologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

ORCID profiles: Tony Marchand, Cédric Pastoret, Charles Herbaux, Astrid Pavlosky, Aspasia Stamatoullas, Christer Nilsson

Cite

APA

Marchand, T., Pastoret, C., Damaj, G., Lebouvier, A., Herbaux, C., Moignet, A., Pavlosky, M., Pavlosky, A., Blouet, A., Eloit, M., Launay, V., Lebreton, P., Stamatoullas, A., Nilsson, C., Ochmann, M., Prola, J., & Lamy, T. (2024). Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. British Journal of Haematology, 205(3), 915-923. https://doi.org/10.1111/bjh.19476

Vancouver

Marchand T, Pastoret C, Damaj G, Lebouvier A, Herbaux C, Moignet A, et al. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. British Journal of Haematology. 2024;205(3):915-923. doi:10.1111/bjh.19476

BibTeX
@article{Marchand2024,
  author = {Marchand, Tony and Pastoret, Cédric and Damaj, Gandhi and Lebouvier, Angélique and Herbaux, Charles and Moignet, Aline and Pavlosky, Miguel and Pavlosky, Astrid and Blouet, Anaise and Eloit, Martin and Launay, Vincent and Lebreton, Pierre and Stamatoullas, Aspasia and Nilsson, Christer and Ochmann, Marlène and Prola, Juliette and Lamy, Thierry},
  title = {Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {3},
  pages = {915--923},
  doi = {10.1111/bjh.19476}
}
Start for free →